CoChat

Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models

Open access
Song, Yafeng, Morales, Leon, Malik, Alock S., Mead, Andrew F., Greer, Christopher D., Mitchell, Marilyn A., Petrov, Mihail T., Su, Leonard T., Choi, Margaret E., Rosenblum, Shira T., Lu, Xiangping, VanBelzen, Daniel J., Krishnankutty, Ranjith K., Balzer, Frederick J., Loro, Emanuele, French, Robert, Propert, Kathleen J., Zhou, Shangzhen, Kozyak, Benjamin W., Nghiem, Peter P., Khurana, Tejvir S., Kornegay, Joe N., Stedman, Hansell H. · 2019 · Nature Medicine
Cited by 97

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

The essential product of the Duchenne muscular dystrophy (DMD) gene is dystrophin1, a rod-like protein2 that protects striated myocytes from contraction-induced injury3,4. Dystrophin-related protein (or utrophin) retains most of the structural and protein binding elements of dystrophin5. Importantly, normal thymic expression in DMD patients6 should protect utrophin by central immunologic tolerance. We designed a codon-optimized, synthetic transgene encoding a miniaturized utrophin (µUtro), deliverable by adeno-associated virus (AAV) vectors. Here, we show that µUtro is a highly functional, non-immunogenic substitute for dystrophin, preventing the most deleterious histological and physiological aspects of muscular dystrophy in small and large animal models. Following systemic administration of an AAV-µUtro to neonatal dystrophin-deficient mdx mice, histological and biochemical markers of myonecrosis and regeneration are completely suppressed throughout growth to adult weight. In the dystrophin-deficient golden retriever model, µUtro non-toxically prevented myonecrosis, even in the most powerful muscles. In a stringent test of immunogenicity, focal expression of µUtro in the deletional-null German shorthaired pointer model produced no evidence of cell-mediated immunity, in contrast to the robust T cell response against similarly constructed µDystrophin (µDystro). These findings support a model in which utrophin-derived therapies might be used to treat clinical dystrophin deficiency, with a favorable immunologic profile and preserved function in the face of extreme miniaturization. A gene therapy vector expressing micro-utrophin provides functional replacement of lost dystrophin, and lacks the adverse immunogenicity associated with direct dystrophin therapy, in rodent and canine models of Duchenne muscular dystrophy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0594-0

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 97

Metadata

Authors
Song, Y., Morales, L., Malik, A. S., Mead, A. F., Greer, C. D., Mitchell, M. A., Petrov, M. T., Su, L. T., Choi, M. E., Rosenblum, S. T., Lu, X., VanBelzen, D. J., Krishnankutty, R. K., Balzer, F. J., Loro, E., French, R., Propert, K. J., Zhou, S., Kozyak, B. W., Nghiem, P. P., Khurana, T. S., Kornegay, J. N., & Stedman, H. H.
Venue
Nature Medicine
Published
2019-10
Volume
25
Issue
10
Pages
1505-1511
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2979165129
Cited by
97
References
15
FWCI
3.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. https://app.cochat.ai/papers/10.1038/s41591-019-0594-0
The paper
Song, Y., Morales, L., Malik, A. S., Mead, A. F., Greer, C. D., Mitchell, M. A., Petrov, M. T., Su, L. T., Choi, M. E., Rosenblum, S. T., Lu, X., VanBelzen, D. J., Krishnankutty, R. K., Balzer, F. J., Loro, E., French, R., Propert, K. J., Zhou, S., Kozyak, B. W., . . . Stedman, H. H. (2019). Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nature Medicine. https://doi.org/10.1038/s41591-019-0594-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.